Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus carboplatin/taxane induction followed by pembrolizumab with or without maintenance olaparib in first-line metastatic squamous NSCLC
jRCT2080224811Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab, olaparib, carboplatin and paclitaxel in Pulmonary squamous cell carcinoma (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival (PFS) in maintenance phase and Overall Survival (OS) in maintenance phase. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2080224811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224811.